Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Just to follow up, It seems like Multi-TAA (so far) have NO life threatening or fatal cytokine release syndrome should be a bigger deal than it is. I follow many different companies and their trial results. The CAR-T companies and the ADC (antibody drug conjugate) companies all seem to have this "severe adverse effects" problem of one kind or the other. Just looked at some results, 423 patients in one trial, 14 complete responses, which is good but is also about 3% CR's and they had 35% "severe adverse effects" which is very not good, as they would not only have a box warning (like Tavley) but also would only be available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) (like Tavley). Plus the cost of these CAR-T / ADC treatments will be in the 1/4 million to 1 million dollar range. I hope the FDA wises up to the benefits of Multi-TAA soon.